Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Co-Altered Lung Adenocarcinoma

被引：0
|
作者：
Cai, Weijing [1 ]
Zhou, Caicun [1 ]
Lin, Dongmei [2 ]
Wu, Chunyan [3 ]
Li, Xuefei [1 ]
Zhao, Chao [1 ]
Zheng, Limou [4 ]
Fei, Ke [5 ]
Hirsch, Fred R. [6 ,7 ]
机构：
[1] Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
[2] Beijing Canc Hosp, Beijing, Peoples R China
[3] Shanghai Pulm Hosp, Pathol, Shanghai, Peoples R China
[4] Xiamen Univ, Translat Med Ctr, Xiamen, Peoples R China
[5] Shanghai Pulm Hosp, Thorac Surg, Shanghai, Peoples R China
[6] Univ Colorado, Ctr Canc, Dept Med, Aurora, CO USA
[7] Univ Colorado, Ctr Canc, Dept Pathol, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
ALK rearrangement; ALK/EGFR co-alteration; lung adenocarcinoma; Intratumoral Heterogeneity;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI10.02
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
    Cai, Weijing
    Lin, Dongmei
    Wu, Chunyan
    Li, Xuefei
    Zhao, Chao
    Zheng, Limou
    Chuai, Shannon
    Fei, Ke
    Zhou, Caicun
    Hirsch, Fred R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3701 - +
  • [2] Clinicophopathologic Features in ALK-Rearranged Lung Adenocarcinoma in the Korea
    Kim, Eun Kyoung
    Choi, Chang-Min
    Lee, Dae Ho
    Choi, Jene
    Jang, Se Jin
    Suh, Cheolwon
    Lee, Jung Shin
    Kim, Sang-We
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S404 - S405
  • [3] Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer
    Rossi, G.
    Baldi, L.
    Barbieri, F.
    Bertolini, F.
    Tiseo, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (05) : 1035 - 1036
  • [4] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
    Imanishi, Naoko
    Yoneda, Kazue
    Taira, Akihiro
    Ichiki, Yoshinobu
    Sato, Naoko
    Hisaoka, Masanori
    Tanaka, Fumihiro
    [J]. SURGICAL CASE REPORTS, 2018, 4
  • [5] The microRNA-mRNA interactions in ALK-rearranged lung adenocarcinoma
    Subat, Sophia
    Inamura, Kentaro
    Ninomiya, Hironori
    Nagano, Hiroko
    Okumura, Sakae
    Ishikawa, Yuichi
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [6] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
    Naoko Imanishi
    Kazue Yoneda
    Akihiro Taira
    Yoshinobu Ichiki
    Naoko Sato
    Masanori Hisaoka
    Fumihiro Tanaka
    [J]. Surgical Case Reports, 4 (1)
  • [7] Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma
    Kwok, Hoi-Hin
    Li, Huiyu
    Yang, Jiashuang
    Deng, Junyang
    Lee, Nerissa Chui-Mei
    Au, Timmy Wing-Kuk
    Sit, Alva Ko-Yung
    Hsin, Michael Kuan-Yew
    Ma, Stephanie Kwai-Yee
    Cheung, Lydia Wai-Ting
    Girard, Luc
    Fujimoto, Junya
    Wistuba, Ignacio Ivan
    Gao, Boning
    Minna, John Dorrance
    Lam, David Chi-Leung
    [J]. CANCER COMMUNICATIONS, 2023, 43 (08) : 951 - 955
  • [8] Lorlatinib in ALK-Rearranged Lung Cancer
    Kuang, Shelley
    Leighl, Natasha B.
    [J]. CANCER CELL, 2021, 39 (01) : 25 - 27
  • [9] Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
    Kim, Hyojin
    Chung, Jin-Haeng
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (02) : 149 - 155
  • [10] Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma
    Nakashima, Takaaki
    Nonoshita, Takeshi
    Hirata, Hidenari
    Inoue, Kouji
    Nagashima, Akira
    Yoshitake, Tadamasa
    Asai, Kaori
    Shioyama, Yoshiyuki
    [J]. IN VIVO, 2020, 34 (01): : 247 - 253
12345